International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

Authors: Rodriguez-Otero, Paula ^*, Usmani, Saad, Cohen, Adam D, van de Donk, Niels W C J, Leleu, Xavier, Gállego Pérez-Larraya, Jaime, Manier, Salomon, Nooka, Ajay K, Mateos, Maria Victoria, Einsele, Hermann, Minnema, Monique, Cavo, Michele, Derman, Benjamin A, Puig, Noemi, Gay, Francesca, Ho, P Joy, Chng, Wee-Joo, Kastritis, Efstathios, Gahrton, Gösta, Weisel, Katja, Nagarajan, Chandramouli, Schjesvold, Fredik, Mikhael, Joseph, Costa, Luciano, Raje, Noopur S, Zamagni, Elena, Hájek, Roman, Weinhold, Niels, Yong, Kwee, Ye, Jing Christine, Sidhana, Surbhi, Merlini, Giampaolo, Martin, Tom, Lin, Yi, Chari, Ajai, Popat, Rakesh, Kaufman, Jonathan L

Source: In The Lancet Oncology May 2024 25(5):e205-e216

Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma

Authors: Hasanali, Zainul S., Razzo, Beatrice, Susanibar-Adaniya, Sandra P., Garfall, Alfred L., Stadtmauer, Edward A., Cohen, Adam D.

Source: In Hematology/Oncology Clinics of North America April 2024 38(2):383-406

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA targeting T-cell engagers in multiple myeloma

Authors: Lee, Holly, Durante, Michael, Skerget, Sheri, Vishwamitra, Deeksha, Benaoudia, Sacha, Ahn, Sungwoo, Poorebrahim, Mansour, Barakat, Elie, Jung, David, Leblay, Noémie, Ziccheddu, Bachisio, Diamond, Benjamin, Papadimitriou, Marios, Cohen, Adam D., Landgren, Ola, Neri, Paola, Maura, Francesco, Bahlis, Nizar J.

Source: In Blood September 2024

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study

Authors: Cohen, Adam D., Hari, Parameswaran, Htut, Myo, Berdeja, Jesus G., Usmani, Saad Z., Madduri, Deepu, Olyslager, Yunsi, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Gries, Katharine S., Fastenau, John M., Valluri, Satish, Deraedt, William, Akram, Muhammad, Crawford, Rebecca, Morrison, Ross, Doward, Lynda, Morgan, Kate, Seldam, Silene ten, Jakubowiak, Andrzej, Jagannath, Sundar

Source: Clinical lymphoma, myeloma & leukemia. 23(1):68-77

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100194273943.0x000001&indx=1&recIds=ETOCvdc_100194273943.0x000001

Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma

Authors: Berdeja, Jesus G., Cohen, Adam D., Martin, Thomas, Madduri, Deepu, Pacaud, Lida, Jagannath, Sundar

Source: Future oncology. 19(18):1235-1247

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100191697641.0x000001&indx=1&recIds=ETOCvdc_100191697641.0x000001

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Authors: Martin, Thomas, Usmani, Saad Z., Berdeja, Jesus G., Agha, Mounzer, Cohen, Adam D., Hari, Parameswaran, Avigan, David, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil C., O'Donnell, Elizabeth, Stewart, A. Keith, Schecter, Jordan M., Goldberg, Jenna D., Jackson, Carolyn C., Yeh, Tzu-Min, Banerjee, Arnob, Allred, Alicia, Zudaire, Enrique, Deraedt, William, Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida, Madduri, Deepu, Jakubowiak, Andrzej, Lin, Yi, Jagannath, Sundar

Source: Journal of clinical oncology. 41(6):1265-1274

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183180201.0x000001&indx=1&recIds=ETOCvdc_100183180201.0x000001

Progressive multifocal leukoencephalopathy in multiple myeloma

Authors: Hoeynck, Brian W., Cohen, Adam D., Stadtmauer, Edward A., Susanibar‐Adaniya, Sandra P., Vogl, Dan T., Waxman, Adam J., Bardsley, Mark, Le, Samantha, LaMaestra, Lexis, Garfall, Alfred L.

Source: European journal of haematology. 110(3):322-329

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173061827.0x000001&indx=1&recIds=ETOCvdc_100173061827.0x000001

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study

Authors: Htut, Myo, Dhakal, Binod, Cohen, Adam D., Martin, Thomas, Berdeja, Jesus G., Usmani, Saad Z., Agha, Mounzer, Jackson, Carolyn C., Madduri, Deepu, Deraedt, William, Zudaire, Enrique, Yeh, Tzu-min, Xu, Xiaoying, Pacaud, Lida, Akram, Muhammad, Jagannath, Sundar

Source: In Clinical Lymphoma, Myeloma and Leukemia December 2023 23(12):882-888

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Authors: Gertz, Morie A., Cohen, Adam D., Comenzo, Raymond L., Kastritis, Efstathios, Landau, Heather J., Libby, Edward N., Liedtke, Michaela, Sanchorawala, Vaishali, Schönland, Stefan, Wechalekar, Ashutosh, Zonder, Jeffrey A., Palladini, Giovanni, Walling, Jackie, Guthrie, Spencer, Nie, Christie, Karp, Carol, Jin, Yuying, Kinney, Gene G., Merlini, Giampaolo

Source: In Blood 5 October 2023 142(14):1208-1218

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Authors: Cohen, Adam D., Mateos, María-Victoria, Cohen, Yael C., Rodriguez-Otero, Paula, Paiva, Bruno, van de Donk, Niels W. C. J., Martin, Thomas, Suvannasankha, Attaya, De Braganca, Kevin C., Corsale, Christina, Schecter, Jordan M., Varsos, Helen, Deraedt, William, Wang, Liwei, Vogel, Martin, Roccia, Tito, Xu, Xiaoying, Mistry, Pankaj, Zudaire, Enrique, Akram, Muhammad, Nesheiwat, Tonia, Pacaud, Lida, Avivi, Irit, San-Miguel, Jesus ^∗

Source: In Blood 19 January 2023 141(3):219-230

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study

Authors: Martin, Thomas, Lin, Yi, Agha, Mounzer, Cohen, Adam D, Htut, Myo, Stewart, A Keith, Hari, Parameswaran, Berdeja, Jesus G, Usmani, Saad Z, Yeh, Tzu-Min, Olyslager, Yunsi, Goldberg, Jenna D, Schecter, Jordan M, Madduri, Deepu, Jackson, Carolyn C, Deraedt, William, Gries, Katharine S, Fastenau, John M, Trudeau, Jeremiah J, Akram, Muhammad, Pacaud, Lida, Jakubowiak, Andrzej, Jagannath, Sundar ^*

Source: In The Lancet Haematology December 2022 9(12):e897-e905

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Authors: Raje, Noopur S, Anaissie, Elias, Kumar, Shaji K, Lonial, Sagar, Martin, Thomas, Gertz, Morie A, Krishnan, Amrita, Hari, Parameswaran, Ludwig, Heinz, O'Donnell, Elizabeth, Yee, Andrew, Kaufman, Jonathan L, Cohen, Adam D, Garderet, Laurent, Wechalekar, Ashutosh F, Terpos, Evangelos, Khatry, Navin, Niesvizky, Ruben, Yi, Qing, Joshua, Douglas E, Saikia, Tapan, Leung, Nelson, Engelhardt, Monika, Mothy, Mohamad, Branagan, Andrew, Chari, Ajai, Reiman, Anthony J, Lipe, Brea, Richter, Joshua, Rajkumar, S Vincent, Miguel, Jesús San, Anderson, Kenneth C, Stadtmauer, Edward A, Prabhala, Rao H, McCarthy, Phillip L, Munshi, Nikhil C

Source: Lancet.Haematology. 9(2):e143-e161

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183249048.0x000001&indx=1&recIds=ETOCvdc_100183249048.0x000001

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Authors: Berdeja, Jesus G ^*, Madduri, Deepu ^*, Usmani, Saad Z, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Stewart, A Keith, Hari, Parameswaran, Htut, Myo, Lesokhin, Alexander, Deol, Abhinav, Munshi, Nikhil C, O'Donnell, Elizabeth, Avigan, David, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J, Olyslager, Yunsi, Banerjee, Arnob, Jackson, Carolyn C, Goldberg, Jenna D, Schecter, Jordan M, Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey, Geng, Dong, Wu, Xiaoling, Carrasco-Alfonso, Marlene J, Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Lin, Yi, Martin, Thomas, Jagannath, Sundar ^*

Source: In The Lancet 24-30 July 2021 398(10297):314-324

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Authors: Costa, Luciano J., Banerjee, Rahul, Mian, Hira, Weisel, Katja, Bal, Susan, Derman, Benjamin A., Htut, Maung M., Nagarajan, Chandramouli, Rodriguez, Cesar, Richter, Joshua, Frigault, Matthew J., Ye, Jing C., van de Donk, Niels W. C. J., Voorhees, Peter M., Puliafito, Benjamin, Bahlis, Nizar, Popat, Rakesh, Chng, Wee Joo, Ho, P. Joy, Kaur, Gurbakhash, Kapoor, Prashant, Du, Juan, Schjesvold, Fredrik, Berdeja, Jesus, Einsele, Hermann, Cohen, Adam D., Mikhael, Joseph, Biru, Yelak, Rajkumar, S. Vincent, Lin, Yi, Martin, Thomas G., Chari, Ajai

Source: Leukemia; March 2025, Vol. 39 Issue: 3 p543-554, 12p

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

Authors: Jadlowsky, Julie K., Hexner, Elizabeth O., Marshall, Amy, Grupp, Stephan A., Frey, Noelle V., Riley, James L., Veloso, Elizabeth, McConville, Holly, Rogal, Walter, Czuczman, Cory, Hwang, Wei-Ting, Li, Yimei, Leskowitz, Rachel M., Farrelly, Olivia, Karar, Jayashree, Christensen, Shannon, Barber-Rotenberg, Julie, Gaymon, Avery, Aronson, Naomi, Bernstein, Wendy, Melenhorst, Jan Joseph, Roche, Aoife M., Everett, John K., Zolnoski, Sonja A., McFarland, Alexander G., Reddy, Shantan, Petrichenko, Angelina, Cook, Emma J., Lee, Carole, Gonzalez, Vanessa E., Alexander, Kathleen, Kulikovskaya, Irina, Ramírez-Fernández, Ángel, Minehart, Janna C., Ruella, Marco, Gill, Saar I., Schuster, Stephen J., Cohen, Adam D., Garfall, Alfred L., Shah, Payal D., Porter, David L., Maude, Shannon L., Levine, Bruce L., Siegel, Donald L., Chew, Anne, McKenna, Stephen, Lledo, Lester, Davis, Megan M., Plesa, Gabriela, Herbst, Friederike, Stadtmauer, Edward A., Tebas, Pablo, DiNofia, Amanda, Haas, Andrew, Haas, Naomi B., Myers, Regina, O’Rourke, Donald M., Svoboda, Jakub, Tanyi, Janos L., Aplenc, Richard, Jacobson, Jeffrey M., Ko, Andrew H., Cohen, Roger B., June, Carl H., Bushman, Frederic D., Fraietta, Joseph A.

Source: Nature Medicine; 20250101, Issue: Preprints p1-11, 11p

B‐cell maturation antigen chimeric antigen receptor T‐cell re‐expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor‐based combination therapy

Authors: Bernabei, Luca, Tian, Lifeng, Garfall, Alfred L., Melenhorst, J. Joseph, Lacey, Simon F., Stadtmauer, Edward A., Vogl, Dan T., Gonzalez, Vanessa E., Plesa, Gabriela, Young, Regina M., Waxman, Adam, Levine, Bruce L., June, Carl H., Milone, Michael C., Cohen, Adam D.

Source: British journal of haematology. 193(4):851-855

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100128758696.0x000001&indx=1&recIds=ETOCvdc_100128758696.0x000001

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Authors: Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, Cohen, Adam D.

Source: Cancer. 127(22):4198-4212

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100132971311.0x000001&indx=1&recIds=ETOCvdc_100132971311.0x000001

Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab

Authors: Freyer, Craig W., Bange, Erin M., Skuli, Sarah, Hsu, Miles, Lin, John, Cuker, Adam, Cohen, Adam D., Garfall, Alfred

Source: Clinical lymphoma, myeloma & leukemia. 21(11):e845-e849

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100168424433.0x000001&indx=1&recIds=ETOCvdc_100168424433.0x000001

Clinical Reasoning: A 49-Year-Old Man With Progressive Numbness, Gait Instability, and Tremors.

Authors: Jones, Felipe J. S., Cohen, Adam D., Karam, Chafic

Source: Neurology; 10/8/2024, Vol. 103 Issue 7, p45-50, 6p

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Authors: Kumar, Shaji K ^*, Jacobus, Susanna J, Cohen, Adam D, Weiss, Matthias, Callander, Natalie, Singh, Avina K, Parker, Terri L, Menter, Alexander, Yang, Xuezhong, Parsons, Benjamin, Kumar, Pankaj, Kapoor, Prashant, Rosenberg, Aaron, Zonder, Jeffrey A, Faber, Edward, Jr, Lonial, Sagar, Anderson, Kenneth C, Richardson, Paul G, Orlowski, Robert Z, Wagner, Lynne I, Rajkumar, S Vincent

Source: In The Lancet Oncology October 2020 21(10):1317-1330